Nonalcoholic Fatty Liver Disease (NAFLD) / Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; diagnosis of non-alcoholic fatty liver disease (NAFLD/MASLD) confirmed via liver biopsy pathology or imaging. 2. Provision of high-quality pathological sections (H&E and Masson staining), complete clinical data, and lifestyle questionnaire information. 3. No history of liver transplantation or systemic anti-fibrotic intervention therapy. 4. Subject (or legal representative) has signed the informed consent form and voluntarily participates in the study.
Exclusion criteria
Exclusion criteria: 1. Substandard quality of pathological sections: blurred images, tissue damage, uneven staining, or evaluable tissue area < 1 cm^2. 2. Concomitant active liver disease: chronic hepatitis B (HBsAg-positive), chronic hepatitis C (HCV-RNA-positive), primary biliary cholangitis, autoimmune hepatitis, etc. 3. Confirmed diagnosis of hepatocellular carcinoma or other hepatic malignancies prior to study enrollment. 4. Pregnant or lactating women. 5. Receipt of immunosuppressants, targeted therapy, or other experimental interventions within the past 3 months. 6. Critical clinical data missing to the extent that core covariate analysis cannot be performed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of HCC and cirrhosis; Predictive accuracy (AUC) of the AI model; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prediction accuracy for metabolic syndrome-related complications (e.g., liver failure, portal hypertension);Clinical utility metrics (PPV, NPV, calibration curve, and decision curve analysis);Interpretability analysis of key pathological imaging features (SHAP values, Class Activation Mapping).; | — |
Countries
China
Contacts
Minhang Hospital Affiliated to Fudan University